Treatment of post transplant relapse of FLT3-ITD mutated AML using 5-azacytidine and sorafenib bitherapy

With the recent progress of allogenic stem cell transplantation (allo-SCT), more patients with Acute Myeloid Leukemia (AML) access to allo-SCT and mortality has decreased1. However, 30-40% of patients relapse, outcome after post-transplant relapse is poor and most patients do not benefit from salvage chemotherapy. Approximately one third of these patients harbor FLT3 internal tandem duplication (FLT3-ITD) which is associated with sensitivity to several Tyrosine Kinase Inhibitors (TKI). Sorafenib is a multikinase inhibitor targeting FLT3 and the Raf/ERK/MAP kinase pathway with single agent clinical activity in FLT3 mutated AML including in patients who had relapsed following allo-SCT2.

Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Selim Sid, Rey Jerome, Charbonnier Aude, D ’Incan Evelyne, Mohty Bilal, Blaise Didier, Norbert Vey Tags: Letter to the Editor Source Type: research